This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): resveratrol, 184072

Description: SRT501 is a proprietary reformulation of resveratrol that is more stable and bioavailable through the use of excipients and optimizing particle size. SRT501 activates SIRT1, a member of the human sirtuin family of enzymes, which are hypothesized to play a key role in an organism's response to stresses (such as heat or starvation) and to be responsible for the lifespan-extending effects of calorie restriction. Specifically, SRT501 acts by increasing mitochondrial activity in pre-clinical models of disease. SIRT1 affects proteins that contribute to cellular regulation, such as apoptosis, cell defenses, and metabolism. Its effect may be mediated through PGC-1alpha (PPAR gamma coactivator-1alpha).

Pre-clinical studies have also shown that SRT501 can increase insulin sensitivity. On the other hand, some studies have shown activation of SIRT1 can have the opposing effect of increasing the genes involved in making more glucose in response to fasting, though Sirtris has not seen this in in vivo with SRT501.

Deal Structure: In April 2008, GlaxoSmithKline and Sirtris announced that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50 (or approx. GBP11.33) per share. Sirtris will become part of GSK's Drug Discovery organisation, while continuing to operate from laboratories in Cambridge, Massachusetts as an autonomous drug discovery unit.

Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. All outstanding stock options will be cancelled with holders receiving the excess of the transactions price over the exercise price.

In June 2008, GlaxoSmithKline announced the successful completion of the tender...See full deal structure in Biomedtracker

SRT501 News

Pink Sheet GSK buys Sirtris

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug